{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-25-000007","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2025-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.178382+00:00","generated_at":"2026-05-23T09:20:33.651905+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Novocure's Optune Lua receives CE Mark for metastatic NSCLC treatment","bullets":["CE Mark for Optune Lua in mNSCLC with immune checkpoint inhibitors or docetaxel after platinum progression.","Phase 3 LUNAR trial: median OS 13.2 months (Optune Lua) vs 9.9 months (control); primary endpoint met.","Subgroup with immune checkpoint inhibitor: median OS 18.5 vs 10.8 months (P=0.03).","Local registration initiated in Germany; launch expected in coming weeks. FDA approval received Oct 2024.","Post-market study of TTFields with docetaxel required as condition; 180 patients, 12-month follow-up."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-25-000007","json":"https://secwatch.observer/filing/0001645113-25-000007.json","markdown":"https://secwatch.observer/filing/0001645113-25-000007.md","text":"https://secwatch.observer/filing/0001645113-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000007/0001645113-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000007/nvcr-20250422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T09:20:33.651905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}